NCCN Clinical Practice Guidelines in. Non-Small Cell Lung Cancer. Version 6.2021. NCCNorg. 2021.

Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18:625–44. https://doi.org/10.1038/s41571-021-00520-1.

Article  PubMed  Google Scholar 

Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413–22. https://doi.org/10.1016/s1470-2045(20)30453-8.

Article  CAS  PubMed  Google Scholar 

Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, et al. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in patients with Stage IIIA(N2) non-small-cell Lung Cancer-A Multicenter single-arm phase II trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2021;39:2872–80. https://doi.org/10.1200/jco.21.00276.

Article  CAS  Google Scholar 

Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:786–95. https://doi.org/10.1016/s1470-2045(20)30140-6.

Article  CAS  PubMed  Google Scholar 

Yan YD, Cui JJ, Fu J, Su YJ, Chen XY, Gu ZC, et al. A Network comparison on Safety Profiling of Immune checkpoint inhibitors in Advanced Lung Cancer. Front Immunol. 2021;12:760737. https://doi.org/10.3389/fimmu.2021.760737.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–30. https://doi.org/10.1016/S0140-6736(18)32409-7.

Article  CAS  PubMed  Google Scholar 

Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008;7:591–607. https://doi.org/10.1038/nrd2290.

Article  CAS  PubMed  Google Scholar 

Kobayashi H, Longmire MR, Ogawa M, Choyke PL, Kawamoto S. Multiplexed imaging in cancer diagnosis: applications and future advances. Lancet Oncol. 2010;11:589–95. https://doi.org/10.1016/S1470-2045(10)70009-7.

Article  PubMed  PubMed Central  Google Scholar 

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852–8. https://doi.org/10.1038/s41591-018-0255-8.

Article  CAS  PubMed  Google Scholar 

Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen G, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9:4664. https://doi.org/10.1038/s41467-018-07131-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou X, Jiang J, Yang X, Liu T, Ding J, Nimmagadda S, et al. First-in-humans evaluation of a PD-L1-Binding peptide PET Radiotracer in Non-small Cell Lung Cancer patients. J Nucl Med. 2022;63:536–42. https://doi.org/10.2967/jnumed.121.262045.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verhaar ER, Woodham AW, Ploegh HL. Nanobodies in cancer. Semin Immunol. 2021;52:101425. https://doi.org/10.1016/j.smim.2020.101425.

Article  CAS  PubMed  Google Scholar 

Wei W, Younis MH, Lan X, Liu J, Cai W. Single-domain antibody theranostics on the Horizon. J Nucl Med. 2022;63:1475–9. https://doi.org/10.2967/jnumed.122.263907.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang EY, Shah K, Nanobodies. Next Generation of Cancer Diagnostics and therapeutics. Front Oncol. 2020;10:1182. https://doi.org/10.3389/fonc.2020.01182.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lv G, Sun X, Qiu L, Sun Y, Li K, Liu Q, et al. PET imaging of Tumor PD-L1 expression with a highly specific nonblocking single-domain antibody. J Nucl Med. 2020;61:117–22. https://doi.org/10.2967/jnumed.119.226712.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma X, Zhou X, Hu B, Li X, Yao M, Li L, et al. Preclinical evaluation and pilot clinical study of [(68)Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging. Eur J Nucl Med Mol Imaging. 2023;50:3838–50. https://doi.org/10.1007/s00259-023-06373-3.

Article  CAS  PubMed  Google Scholar 

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):S122–50. https://doi.org/10.2967/jnumed.108.057307.

Article  CAS  Google Scholar 

Smit J, Borm FJ, Niemeijer AN, Huisman MC, Hoekstra OS, Boellaard R, et al. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in patients with Advanced-Stage Non-small Cell Lung Cancer. J Nucl Med. 2022;63:686–93. https://doi.org/10.2967/jnumed.121.262473.

Article  CAS  PubMed  Google Scholar 

Nienhuis PH, Antunes IF, Glaudemans A, Jalving M, Leung D, Noordzij W, et al. (18)F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.121.262368.

Article  PubMed  Google Scholar 

Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, et al. (89)Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. Ann Oncol. 2022;33:80–8. https://doi.org/10.1016/j.annonc.2021.10.213.

Article  CAS  PubMed  Google Scholar 

Xing Y, Chand G, Liu C, Cook GJR, O’Doherty J, Zhao L, et al. Early phase I study of a (99m)Tc-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer. J Nucl Med. 2019;60:1213–20. https://doi.org/10.2967/jnumed.118.224170.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Cao M, Wu Y, Malih S, Xu D, Yang E, et al. Preclinical development of novel PD-L1 tracers and first-in-human study of [(68)Ga]Ga-NOTA-RW102 in patients with lung cancers. J Immunother Cancer. 2024;12. https://doi.org/10.1136/jitc-2024-008794.

Derlin T, Schmuck S, Juhl C, Zörgiebel J, Schneefeld SM, Walte ACA, et al. PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:913–22. https://doi.org/10.1007/s00259-017-3924-9.

Article  CAS  PubMed  Google Scholar 

Crauwels M, Massa S, Martin C, Betti C, Ballet S, Devoogdt N, et al. Site-specific Radioactive labeling of Nanobodies. In: Nevoltris D, Chames P, editors. Antibody Engineering: methods and protocols. New York, NY: Springer New York; 2018. pp. 505–40.

Chapter  Google Scholar 

Tao X, Li N, Wu N, He J, Ying J, Gao S, et al. The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47:1209–19. https://doi.org/10.1007/s00259-020-04711-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Federico A, Alden SL, Smithy JW, Ricciuti B, Alessi JV, Wang X, et al. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Ann Oncol. 2024;35:902–13. https://doi.org/10.1016/j.annonc.2024.06.014.

Article  CAS  PubMed  Google Scholar 

Wu Y, Xu D, Gu Y, Li G, Wang H, Cao M, et al. Assessment of PD-L1 expression in Non-small Cell Lung cancers using [(68)Ga]Ga-DOTA-WL12 PET/CT. Small Methods. 2024;e2400358. https://doi.org/10.1002/smtd.202400358.

Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, et al. IASLC Multidisciplinary recommendations for Pathologic Assessment of Lung Cancer resection specimens after neoadjuvant therapy. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2020;15:709–40. https://doi.org/10.1016/j.jtho.2020.01.005.

Article  CAS